Attributes | Values |
---|
rdf:type
| |
http://linked.open...gbank/description
| - Benzotropine is a centrally-acting, antimuscarinic agent used as an adjunct in the treatment of Parkinson’s disease. It may also be used to treat extrapyramidal reactions, such as dystonia and Parkinsonism, caused by antipsychotics (e.g. phenothiazines). Symptoms of Parkinson’s disease and extrapyramidal reactions arise from decreases in dopaminergic activity which creates an imbalance between dopaminergic and cholinergic activity. Anticholinergic therapy is thought to aid in restoring this balance leading to relief of symptoms. In addition to its anticholinergic effects, benztropine also inhibits the reuptake of dopamine at nerve terminals via the dopamine transporter. Benzotropine also produces antagonistic effects at the histamine H1 receptor. (en)
|
http://linked.open...y/drugbank/dosage
| |
http://linked.open...generalReferences
| - # Wszola BA, Newell KM, Sprague RL: Risk factors for tardive dyskinesia in a large population of youths and adults. Exp Clin Psychopharmacol. 2001 Aug;9(3):285-96. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11534539 # van Harten PN, Hoek HW, Matroos GE, Koeter M, Kahn RS: Intermittent neuroleptic treatment and risk for tardive dyskinesia: Curacao Extrapyramidal Syndromes Study III. Am J Psychiatry. 1998 Apr;155(4):565-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9546009 (en)
|
http://linked.open...gy/drugbank/group
| |
http://linked.open...ugbank/indication
| - For use as an adjunct in the therapy of all forms of parkinsonism and also for use in the control of extrapyramidal disorders due to neuroleptic drugs. (en)
|
http://linked.open...bank/manufacturer
| |
sameAs
| |
Title
| |
adms:identifier
| |
http://linked.open...mechanismOfAction
| - Benztropine is a selective M1 muscarinic acetylcholine receptor antagonist. It is able to discriminate between the M1 (cortical or neuronal) and the peripheral muscarinic subtypes (cardiac and glandular). Benztropine partially blocks cholinergic activity in the CNS, which is responsible for the symptoms of Parkinson's disease. It is also thought to increase the availability of dopamine, a brain chemical that is critical in the initiation and smooth control of voluntary muscle movement. (en)
|
http://linked.open...drugbank/packager
| |
http://linked.open.../drugbank/synonym
| - Benztropine (en)
- Tropine Benzohydryl Ether (en)
- 3-alpha-(diphenylmethoxy)tropane (en)
- 3alpha-(Diphenylmethoxy)-1alphah,5alphah-tropane (en)
- 3alpha-(Diphenylmethoxy)tropane (en)
- 3endo-benzhydryloxytropane (en)
- 3α-(diphenylmethoxy)-1αH,5αH-tropane (en)
- 3α-(diphenylmethoxy)tropane (en)
- Benzatropina (en)
- Benzatropinum (en)
- Benzhydryl 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ether (en)
- 3alpha-Benzhydryloxy-8-methyl-8-azabicyclo[3.2.1]octane (en)
- 3α-benzhydryloxy-8-methyl-8-azabicyclo[3.2.1]octane (en)
|
http://linked.open...drugbank/toxicity
| - Signs of overdose include confusion, nervousness, listlessness, hallucinations, dizziness; muscle weakness, ataxia, dry mouth, mydriasis, blurred vision, palpitations, tachycardia, elevated blood pressure, nausea, vomiting, dysuria, numbness of fingers, headache, delirium, coma, shock, convulsions, respiratory arrest, anhidrosis, hyperthermia, glaucoma, and constipation. (en)
|
http://linked.open.../drug/hasAHFSCode
| |
http://linked.open...k/foodInteraction
| - Avoid alcohol. (en)
- Take with food to reduce irritation. (en)
|
http://linked.open...nk/proteinBinding
| - ~95% to serum proteins (en)
|
http://linked.open...ogy/drugbank/salt
| |
http://linked.open...ynthesisReference
| - Phillips, R.F.; US. Patent 2,595,405; May 6, 1952; assigned to Merck & Co., Inc. (en)
|
http://linked.open...y/mesh/hasConcept
| |
foaf:page
| |
http://linked.open...ugbank/IUPAC-Name
| |
http://linked.open...gy/drugbank/InChI
| |